EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dihydromyricetin Inhibits M1 Macrophage Polarization in Atherosclerosis by Modulating miR-9-Mediated SIRT1/NF-κB Signaling Pathway

Zhousheng Yang iD, Tianyu Li, Chunyan Wang, Mingyu Meng, Shenglan Tan iD, Lei Chen iD

Mediators of Inflammation · 17.05.2023 · 2023 · 1-11

DOI: 10.1155/2023/2547588 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Mediators of Inflammation, erschienen am 17.05.2023. Verfasst von Zhousheng Yang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The People's Hospital of Guangxi Zhuang Autonomous Region, Guangxi Academy of Medical Sciences, Nanning 530021, China. Hauptthemen laut MEDLINE: NF-kappa B, MicroRNAs. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hunan Administration of Traditional Chinese Medicine Grant, Central South University, ChangSha Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dihydromyricetin (DMY), a natural flavonoid compound extracted from the stems and leaves of Ampelopsis grossedentata, has been found as a potential therapeutic chemical for treating atherosclerosis. This study explores the underlying mechanism of DMY repressing M1 macrophage polarization in atherosclerosis. We showed that DMY treatment markedly decreased M1 macrophage markers (e.g., Tnf-α and IL-1β) and p65-positive macrophage numbers in the vessel wall of Apoe-deficient (Apoe–/–) mice. Overexpression of miR-9 or knockdown of SIRT1 in macrophages reversed the effect of DMY on M1 macrophage polarization. The data we presented in the study indicate that the miR-9-mediated SIRT1/NF-κB pathway plays a pivotal role in M1 macrophage polarization and is one of the molecular mechanisms underlying the anti-atherosclerosis effects of DMY. We provide new solid evidence that DMY may be explored as a potential therapeutic adjuvant for treating atherosclerosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NF-kappa BMicroRNAsMiceAnimalsSirtuin 1Signal TransductionMacrophagesApolipoproteins EFlavonols

Substanzen

NF-kappa BSirtuin 1MicroRNAsApolipoproteins EdihydromyricetinFlavonolsSirt1 protein, mouseMIRN9 microRNA, mouse

Autor:innen und Institutionen

  • Department of Pharmacy, The People's Hospital of Guangxi Zhuang Autonomous Region, Guangxi Academy of Medical Sciences, Nanning 530021, China.
  • Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China 410011.
  • Institute of Clinical Pharmacy, Central South University, Changsha, China 410011.

ORCID-Profile: Zhousheng Yang, Shenglan Tan, Lei Chen

Förderung

  • Hunan Administration of Traditional Chinese Medicine Grant
  • Central South University
  • ChangSha Natural Science Foundation of China
  • Natural Science Foundation of Hunan Province
  • Natural Science Foundation of Guangxi Province
  • National Natural Science Foundation of China

Zitieren

APA

Yang, Z., Li, T., Wang, C., Meng, M., Tan, S., & Chen, L. (2023). Dihydromyricetin Inhibits M1 Macrophage Polarization in Atherosclerosis by Modulating miR-9-Mediated SIRT1/NF-κB Signaling Pathway. Mediators of Inflammation, 2023, 1-11. https://doi.org/10.1155/2023/2547588

Vancouver

Yang Z, Li T, Wang C, Meng M, Tan S, Chen L. Dihydromyricetin Inhibits M1 Macrophage Polarization in Atherosclerosis by Modulating miR-9-Mediated SIRT1/NF-κB Signaling Pathway. Mediators of Inflammation. 2023;2023:1-11. doi:10.1155/2023/2547588

BibTeX
@article{Yang2023,
  author = {Yang, Zhousheng and Li, Tianyu and Wang, Chunyan and Meng, Mingyu and Tan, Shenglan and Chen, Lei},
  title = {Dihydromyricetin Inhibits M1 Macrophage Polarization in Atherosclerosis by Modulating miR-9-Mediated SIRT1/NF-κB Signaling Pathway},
  journal = {Mediators of Inflammation},
  year = {2023},
  volume = {2023},
  pages = {1--11},
  doi = {10.1155/2023/2547588}
}
Kostenlos starten →